Close Menu

NEW YORK (GenomeWeb) – Loxo Oncology announced today that it has formed a collaboration with Roche subsidiary Ventana Medical Systems to develop and commercialize a test to identify patients likely to respond to the cancer drug larotrectinib.

Loxo's larotrectinib — also known as LOXO-101 — is an oral inhibitor of tropomyosin receptor kinases (TRK), a family of proteins associated with cellular signaling and tumor growth. The drug is currently under phase I and II testing as a treatment for tumors with TRK fusions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.